How is blinatumomab (Blincyto) administered?

Blincyto (blinatumomab) is administered by continuous intravenous infusion at a constant flow rate for up to 96 hours using a programmable, lockable, non-elastomeric pump with an alarm and intravenous tubing containing a sterile, non-pyrogenic, low protein-binding 0.2 micrometre in-line filter.